Cat  |   Cas  |   Eng
The InstituteResearchWhat's onPlatformsJoin usTools

TGF-beta and cancer

Research lines

  • Role of TGF-beta in the molecular mechanisms that regulate tumor cell plasticity, migration and invasion.
  • Role of the NADPH oxidase NOX4 in liver regeneration and hepatocarcinogenesis. Cross-talk with the TGF-β and EGF receptor pathways.
  • SPARC and miR-29ab, friends or foes in melanoma metastasis? Cross-talk with the TGF-β pathway.

Selected papers (2013 – 2017)


Resminostat induces changes in epithelial plasticity of hepatocellular carcinoma cells and sensitizes them to sorafenib-induced apoptosis.

Soukupova J, Bertran E, Peñuelas-Haro I, Urdiroz-Urricelqui U, Borgman M, Kohlhof H, Fabregat I.

Oncotarget. 2017 Nov 30;8(66):110367-110379.


The level of caveolin-1 expression determines response to TGF-β as a tumour suppressor in hepatocellular carcinoma cells.

Moreno-Càceres J, Caballero-Díaz D, Nwosu ZC, Meyer C, López-Luque J, Malfettone A, Lastra R, Serrano T, Ramos E, Dooley S, Fabregat I.

Cell Death Dis. 2017 Oct 12;8(10):e3098.


Role of the Transforming Growth Factor-β in regulating hepatocellular carcinoma oxidative metabolism.

Soukupova J, Malfettone A, Hyroššová P, Hernández-Alvarez MI, Peñuelas-Haro I, Bertran E, Junza A, Capellades J, Giannelli G, Yanes O, Zorzano A, Perales JC, Fabregat I.

Sci Rep. 2017 Oct 2;7(1):12486.


AURKA Overexpression Is Driven by FOXM1 and MAPK/ERK Activation in Melanoma Cells Harboring BRAF or NRAS Mutations: Impact on Melanoma Prognosis and Therapy.

Puig-Butille JA, Vinyals A, Ferreres JR, Aguilera P, Cabré E, Tell-Martí G, Marcoval J, Mateo F, Palomero L, Badenas C, Piulats JM, Malvehy J, Pujana MA, Puig S, Fabra À.

J Invest Dermatol. 2017 Jun;137(6):1297-1310.


Transforming growth factor-β-induced plasticity causes a migratory stemness phenotype in hepatocellular carcinoma.

Malfettone A, Soukupova J, Bertran E, Crosas-Molist E, Lastra R, Fernando J, Koudelkova P, Rani B, Fabra Á, Serrano T, Ramos E, Mikulits W, Giannelli G, Fabregat I.

Cancer Lett. 2017 Apr 28;392:39-50.


The NADPH oxidase NOX4 represses epithelial to amoeboid transition and efficient tumour dissemination.

Crosas-Molist E, Bertran E, Rodriguez-Hernandez I, Herraiz C, Cantelli G, Fabra À, Sanz-Moreno V, Fabregat I.

Oncogene. 2017 May 25;36(21):3002-3014.


New Insights into the Crossroads between EMT and Stemness in the Context of Cancer.

Fabregat I, Malfettone A, Soukupova J.

J Clin Med. 2016 Mar 12;5(3). pii: E37. Review.


Caveolin-1-dependent activation of the metalloprotease TACE/ADAM17 by TGF-β in hepatocytes requires activation of Src and the NADPH oxidase NOX1.

Moreno-Càceres J, Mainez J, Mayoral R, Martín-Sanz P, Egea G, Fabregat I.

FEBS J. 2016 Apr;283(7):1300-10.


TGF-β signalling and liver disease.

Fabregat I, Moreno-Càceres J, Sánchez A, Dooley S, Dewidar B, Giannelli G, Ten Dijke P; IT-LIVER Consortium.

FEBS J. 2016 Jun;283(12):2219-32. State of the Art Review.


Cross-Talk Between TGF-β and NADPH Oxidases During Liver Fibrosis and Hepatocarcinogenesis.

Crosas-Molist E, Bertran E, Fabregat I.

Curr Pharm Des. 2015;21(41):5964-76. Review.


Dissecting the role of epidermal growth factor receptor catalytic activity during liver regeneration and hepatocarcinogenesis.

López-Luque J, Caballero-Díaz D, Martinez-Palacián A, Roncero C, Moreno-Càceres J, García-Bravo M, Grueso E, Fernández A, Crosas-Molist E, García-Álvaro M, Addante A, Bertran E, Valverde AM, González-Rodríguez Á, Herrera B, Montoliu L, Serrano T, Segovia JC, Fernández M, Ramos E, Sánchez A, Fabregat I.

Hepatology. 2016 Feb;63(2):604-19.


Role of NADPH oxidases in the redox biology of liver fibrosis.

Crosas-Molist E, Fabregat I.

Redox Biol. 2015 Dec;6:106-11. Review.


Mechanisms regulating cell membrane localization of the chemokine receptor CXCR4 in human hepatocarcinoma cells.

Cepeda EB, Dediulia T, Fernando J, Bertran E, Egea G, Navarro E, Fabregat I.

Biochim Biophys Acta. 2015 May;1853(5):1205-18.


The utility of ancillary tests in monitoring cutaneous melanoma patients to detect visceral metastasis.

Ferreres JR, Marcoval J, Fodge K, de Olza MO, Viñals A, Fabra A.

J Eur Acad Dermatol Venereol. 2015 Dec;29(12):2493-5.


A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells.

Fernando J, Malfettone A, Cepeda EB, Vilarrasa-Blasi R, Bertran E, Raimondi G, Fabra À, Alvarez-Barrientos A, Fernández-Salguero P, Fernández-Rodríguez CM, Giannelli G, Sancho P, Fabregat I.

Int J Cancer. 2015 Feb 15;136(4):E161-72.


Caveolin-1 is required for TGF-β-induced transactivation of the EGF receptor pathway in hepatocytes through the activation of the metalloprotease TACE/ADAM17.

Moreno-Càceres J, Caja L, Mainez J, Mayoral R, Martín-Sanz P, Moreno-Vicente R, Del Pozo MÁ, Dooley S, Egea G, Fabregat I.

Cell Death Dis. 2014 Jul 17;5:e1326.


The NADPH oxidase NOX4 inhibits hepatocyte proliferation and liver cancer progression.

Crosas-Molist E, Bertran E, Sancho P, López-Luque J, Fernando J, Sánchez A, Fernández M, Navarro E, Fabregat I.

Free Radic Biol Med. 2014 Apr;69:338-47.


TGF-beta signaling in cancer treatment.

Fabregat I, Fernando J, Mainez J, Sancho P.

Curr Pharm Des. 2014;20(17):2934-47. Review.


Patterns of visceral metastasis in cutaneous melanoma: a descriptive study.

Marcoval J, Ferreres JR, Martín C, Gómez S, Penín RM, Ochoa de Olza M, Fabra Á.

Actas Dermosifiliogr. 2013 Sep;104(7):593-7.


Overactivation of the TGF-β pathway confers a mesenchymal-like phenotype and CXCR4-dependent migratory properties to liver tumor cells.

Bertran E, Crosas-Molist E, Sancho P, Caja L, Lopez-Luque J, Navarro E, Egea G, Lastra R, Serrano T, Ramos E, Fabregat I.

Hepatology. 2013 Dec;58(6):2032-44.

imatge personal

Group leader

Isabel Fabregat
+34 932607828
© 2018 IDIBELL

Results by pageInitial date
Select date
TitleFinal date
Select date

Your password is about to expire. Please, write in a new password to continue

Remember this password allows you to access to all IDIBELL�s web applications

New password:
Confirm new password:


Your password is about to expire. Please, write in a new password to continue

Remember this password allows you to access to all IDIBELL�s web applications

New password:
Confirm new password:



Passwords doesn�t match
The password must have at least 6 characters
The new password can not contain special characters
User register

Second Surname



Encara no heu contestat l'enquesta de satisfacci� sobre la p�ndola formativa sobre patents. No trigareu m�s de cinc minuts a fer-ho. La vostra opini� �s molt important per millorar l�IDIBELL.

Voleu fer l�enquesta ara?



Further personal and contact information is needed to maintain IDIBELL databases.

Do you wish to fill the form now?



Please, remember to introduce your holiday�s planning in the application